In keratinocytes, the activation of FFAR1 receptors by GW9508 (Figure 1), an FFAR1 and FFAR4 agonist, reduced the release of several chemokines, such as CCL5 and CCL17 (C-C motif chemokine ligands 5 and 17), and attenuated skin immune inflammation [10]. Here, CCL5 is linked to neoplasm.